Antibody elimination by apheresis in living donor liver transplant recipients

被引:6
作者
Kawagishi, N
Ohkohchi, N
Fujimori, K
Orii, T
Koyamada, N
Kikuchi, H
Sekiguchi, S
Tsukamoto, S
Sato, T
Satomi, S
机构
[1] Tohoku Univ, Grad Sch Med, Div Adv Surg Sci & Technol, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Tohoku Univ, Dept Blood Purificat, Sendai, Miyagi 980, Japan
来源
THERAPEUTIC APHERESIS | 2001年 / 5卷 / 06期
关键词
crossmatch; ABO incompatible; liver transplantation; living donor;
D O I
10.1046/j.1526-0968.2001.00376.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the present study, we investigated retrospectively the indications and the efficacy of the elimination of preexisting antiallogeneic antibodies in liver transplant recipients. Three patients who were ABO blood type incompatible were subjected to plasmapheresis and double filtration plasmapheresis before the living donor liver transplantation (LDLTx), and the titers decreased to less than 8. After transplantation, plasmapheresis was also performed in 3 cases, and continuous hemodiafiltration in 1 case, and in 2 out of these 3 patients acute rejection was recognized. Two patients who were crossmatch positive were subjected to plasmapheresis before transplantation, and the T warm titers were reduced to less than Score 2. These 2 patients had no acute rejections after transplantation. We conclude that in liver transplant patients apheresis is effective to prevent acute rejection induced by preexisting anti-A and/or anti-B antibodies and anti-donor specific antibodies before transplantation, but it is not effective in a patient with accelerated humoral rejection occurring after transplantation.
引用
收藏
页码:449 / 454
页数:6
相关论文
共 17 条
  • [1] The effect of a positive T-lymphocytotoxic crossmatch on hepatic allograft survival and rejection
    Bathgate, AJ
    McColl, M
    Garden, OJ
    Forsythe, JLR
    Madhavan, KK
    Hayes, PC
    [J]. LIVER TRANSPLANTATION AND SURGERY, 1998, 4 (04): : 280 - 284
  • [2] BELLE SH, 1993, CLIN TRANSPLANTS 199, P17
  • [3] IGG DONOR-SPECIFIC CROSS-MATCHES ARE NOT ASSOCIATED WITH GRAFT-REJECTION OR POOR GRAFT-SURVIVAL AFTER LIVER-TRANSPLANTATION - AN ASSESSMENT BY CYTOTOXICITY AND FLOW-CYTOMETRY
    DONALDSON, PT
    THOMSON, LJ
    HEADS, A
    UNDERHILL, JA
    VAUGHAN, RW
    ROLANDO, N
    WILLIAMS, R
    [J]. TRANSPLANTATION, 1995, 60 (09) : 1016 - 1023
  • [4] Large, single center investigation of the immunogenetic factors affecting liver transplantation
    Doran, TJ
    Geczy, AF
    Painter, D
    McCaughan, G
    Sheil, AGR
    Süsal, C
    Opelz, G
    [J]. TRANSPLANTATION, 2000, 69 (07) : 1491 - 1498
  • [5] Assessing risk in liver transplantation - Special reference to the significance of a positive cytotoxic crossmatch
    Doyle, HR
    Marino, IR
    Morelli, F
    Doria, C
    Aldrighetti, L
    McMichael, J
    Martell, J
    Gayowski, T
    Starzl, TE
    [J]. ANNALS OF SURGERY, 1996, 224 (02) : 168 - 177
  • [6] ERNST C, 1984, AM J PATHOL, V117, P451
  • [7] THE USE OF ABO-INCOMPATIBLE GRAFTS IN LIVER-TRANSPLANTATION - A LIFESAVING PROCEDURE IN HIGHLY SELECTED PATIENTS
    FARGES, O
    KALIL, AN
    SAMUEL, D
    SALIBA, F
    ARULNADEN, JL
    DEBAT, P
    BISMUTH, A
    CASTAING, D
    BISMUTH, H
    [J]. TRANSPLANTATION, 1995, 59 (08) : 1124 - 1133
  • [8] SPECIFIC ABSORPTION OF LYMPHOCYTOTOXIC ALLOANTIBODIES BY THE LIVER IN INBRED RATS
    GUGENHEIM, J
    AMOROSA, L
    GIGOU, M
    FABIANI, B
    ROUGER, P
    GANE, P
    REYNES, M
    BISMUTH, H
    [J]. TRANSPLANTATION, 1990, 50 (02) : 309 - 313
  • [9] Haberal M, 1996, TRANSPLANT P, V28, P2336
  • [10] Hashimoto T, 1996, TRANSPLANT P, V28, P1217